Advanced Search

Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2016 Nov 08

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2016 Nov 08

Cumulative review and meta-analyses the association between MTHFR rs1801133 polymorphism and breast cancer risk: a pooled analysis of 83 studies with 74,019 participants

Yun ZHANG 1, Hongjun JIA 2, Shoufeng WANG 1, Dazhi JIANG 3

1 Department of Oncology, Linyi Peoples’ Hospital, Linyi, China; 2 Department of Radiotherapy, Linyi Peoples’ Hospital, Linyi, China; 3 Department of Thoracic Surgery, Linyi Peoples’ Hospital, Linyi, China

BACKGROUND: The association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and breast cancer risk has been extensively explored, but their results are conflicting rather than conclusive. To clarify the precise effects of MTHFR polymorphisms on the risk of breast cancer, a systemic review and most comprehensive meta-analysis of all available studies relating MTHFR rs1801133 gene polymorphism to the risk of breast cancer was conducted.
METHODS: Eligible articles were identified by search of databases including Medline (Mainly PubMed), Embase, Web of Science, Chinese Biomedical Literature database (CBM), CNKI and Wanfang Medical databases. Crude ORs with 95% CIs were used to assess the strength of association.
RESULTS: Finally, a total of 83 studies with 35,029 cases and 38,990 controls were included. Overall, MTHFR rs1801133 gene polymorphism was proved to contribute to the risk of breast cancer under all genetic models (TT vs. CC: Pheterogeneity <0.001 , OR = 1.141, 95%CI = 1.065 –1.222, P <0.001; TT vs. CT: Pheterogeneity <0.001, OR = 1.085, 95%CI =1.021 – 1.154, P = 0.009; TT + CT vs. CC: Pheterogeneity <0.001, OR =1.040, 95%CI = 1.020 – 1.061, P <0.001; TT vs. CC + CT: Pheterogeneity<0.001, OR = 1.131, 95%CI = 1.052 – 1.215, P = 0.0478; T allele vs. C allele: Pheterogeneity <0.001, OR = 1.040, 95%CI = 1.009 – 1.071, P = 0.010).
CONCLUSION: The results of this meta-analysis suggest that MTHFR rs1801133 gene polymorphism may the therapeutic target for breast cancer.

language: English


FULL TEXT  REPRINTS

top of page